[New drugs for small animals in 2021]

Area of Science:

• Veterinary Pharmacology
• Small Animal Therapeutics
• Pharmaceutical Market Analysis

Background:

• The German veterinary market continuously evolves with new therapeutic options for small animals.
• Monitoring new drug releases is crucial for veterinary professionals and pet owners.
• Understanding recent pharmaceutical advancements aids in informed treatment decisions.

Purpose of the Study:

• To document and categorize novel pharmaceutical agents released for small animals in Germany in 2021.
• To provide an overview of new formulations, combinations, and reapproved drugs.
• To highlight key advancements in small animal pharmacotherapy.

Main Methods:

• Review of the German pharmaceutical market for veterinary products in 2021.
• Identification and classification of newly released drugs for small animals.
• Categorization based on active substance, therapeutic class, and formulation changes.

Main Results:

• Eight novel pharmaceutical agents were introduced, including monoclonal antibodies (bedinvetmab, frunevetmab), an NSAID (enflioxib), an ectoparasiticide (esafoxolaner), an anti-hemorrhagic (etamsylate), an antidepressant (mirtazapine), an ophthalmic agent (tetryzoline), and a cytostatic (tigilanol tiglate).
• No active substance received an animal species extension.
• Additional releases included new formulations, altered active ingredient content, new combinations, a new administration route, and reapproved active ingredients for specific species.

Conclusions:

• The German market saw significant diversification in small animal pharmaceuticals in 2021.
• Innovations included novel drug classes and improvements to existing therapies.
• These advancements offer expanded therapeutic choices for various small animal conditions.